Lantheus Holdings



First Quarter 2021 Financial Results

FIND > FIGHT > FOLLOW™

May 4, 2021

Mary Anne Heino
President and CEO

Bob Marshall
CFO and Treasurer

Mark Kinarney
Sr. Director, Investor Relations

Lantheus Holdings

- Q1 2021 Highlights & Business Update
- Q1 2021 Financial Update
- Closing Remarks
- Q&A

Safe Harbor Statements

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding potential U.S. Food and Drug Administration ("FDA") approval of PyL, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "anticipate," "believe," "confident," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "will" and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include : (i) the impact of the global COVID-19 pandemic on our business, financial conditions or prospects, or on the timing and enrollment of our clinical trials; (ii) continued market expansion and penetration for our commercial products, particularly DEFINITY, in the face of segment competition and potential generic competition as a result of patent and regulatory exclusivity expirations; (iii) our efforts in new product development, including for PyL, our prostate cancer diagnostic imaging agent, including our ability to obtain FDA approval of PyL in 2021, and new clinical applications for our products; (iv) our dependence upon third parties for the manufacture and supply of PyL and the timing of that manufacturing capacity becoming available; (v) the global Molybdenum-99 supply; (vi) our products manufactured at Jubilant HollisterStier and our recently-approved modified formulation of DEFINITY ("DEFINITY RT") to be commercially manufactured at Samsung Biologics; (vii) the continued integration of the Progenics product and product candidate portfolio into our business following the June 2020 consummation of the Progenics acquisition; (viii) our ability to use in-house manufacturing capacity; (ix) the expected timing for commercialization of products we or our strategic partners may develop, including flurpiridaz F 18; (x) our ability to develop highly contextualized assessments of disease burden using artificial intelligence; and (xi) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q)

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; and free cash flow. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company's reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

- **Q1 2021 Highlights & Business Update**
- Q1 2021 Financial Update
- Closing Remarks
- Q&A

Diversified Portfolio

Our diversified portfolio of commercial and pipeline assets

position the company for sustained and diversified revenue growth

Continued to successfully execute against our financial and operational strategies while keeping the safety of Lantheus employees a top priority

Nearly one year after we acquired Progenics:

Execution against our established milestones is well advanced

Significantly invested in our business while overachieving on target run-rate savings

Diversified Portfolio Positions the Company for Sustained and Diversified Revenue Growth

THREE PORTFOLIO CATEGORIES

1 PRECISION DIAGNOSTICS

- DEFINITY® VIAL FOR (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION
- DEFINITY RT (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION
- TechneLite® Technetium Tc 99m Generator
- Xenon Xe 133 Gas
- NEUROLITE® Kit for the Preparation of Technetium Tc 99m Bicisate for Injection
- Cardiolite® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection
- Thallium — Thallous Chloride Tl 201 Injection
- Gallium — Gallium Citrate Ga 67 Injection

2 RADIOPHARMACEUTICAL ONCOLOGY

- AZEDRA® iobenguane I 131 injection for intravenous use
- QUADRAMET® (SAMARIUM SM 153 LEXIDRONAM INJECTION)
- FDG*
- PyL™**
- 1095**
- LMI 1195**

3 STRATEGIC PARTNERSHIPS & OTHER

Pharma Services - Microbubble

- CARTHERA Advanced Brain Therapy Through Innovation
- CEREVAST™
- INSIGHTEC®
- AHN

Pharma Services - Biomarkers

- NTI-1309** NORIA
- NM-01** NANOMAB
- BAYER ***
- POINT BIOPHARMA ***
- REGENERON ***

- aBSI AUTOMATED BONE SCAN INDEX
- aPROMISE
- RELISTOR® methylnaltrexone bromide — BAUSCH Health
- PyL™** — CURIUM™ EU ONLY
- Flurpiridaz** — GE Healthcare
- 1404** — RCTOP

*FDG sales are 2020 through January 2021 due to divestiture of Puerto Rico operations; **product candidates; ***Revenue will be reported under the Radiopharmaceutical Oncology category.

Precision Diagnostics

DEFINITY is an injectable ultrasound enhancing agent that enhances clinicians' view of the left ventricle of the heart during an echocardiogram to aid with diagnosis

TechneLite is a Technetium (Tc-99m) generator that provides the essential nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolite and other Tc-99m-based radiopharmaceuticals used in nuclear medicine procedures

Xenon-133 is an inhaled radiopharmaceutical imaging agent primarily used to image the lungs and evaluate pulmonary function and may also be used to assess cerebral blood flow

DEFINITY: A Trusted Choice for Nearly 20 Years

PRECISION DIAGNOSTICS

DEFINITY®
VIAL FOR (Perflutren Lipid Microsphere)
INJECTABLE SUSPENSION

- Recovery of our business beginning in early February
- Sales team continued to engage through digital technology, including virtual training programs, adding in-person meetings as available; however, this is regionally dependent
- Remain on-track to submit our sNDA for in-house manufacturing later in 2021
  - Provides supply chain redundancy
  - Margin expansion opportunity

Key Commercial Nuclear Medicine Products

PRECISION DIAGNOSTICS

- Continue to see demand build back toward pre-COVID levels
- Molybdenum-99 supply steady throughout quarter
- International transportation logistics remain complex

- Continues to be negatively impacted by limited utilization of in-hospital respiratory inhalation procedures due to concern of COVID-19 transmission

Radiopharmaceutical Oncology

AZEDRA® iobenguane I 131 injection for intravenous use

AZEDRA is a precision radiopharmaceutical therapy for rare neuroendocrine tumors – pheochromocytomas and paragangliomas



PyL (also known as 18F-DCFPyL) is a fluorine 18-based PSMA-targeted PET imaging agent for prostate cancer that enables visualization of primary tumors as well as bone and soft tissue metastases

1095 (also known as I-131-1095) is a PSMA-targeted iodine-131 labeled small molecule that is designed to deliver beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues

PyL image from Pouliot F. *J Clin Oncol*. 2020;38(suppl 6): abstract 9.

AZEDRA®: First and Only FDA Approved Treatment for Patients with Advanced or Metastatic Pheochromocytoma or Paraganglioma

RADIOPHARMACEUTICAL ONCOLOGY

AZEDRA®
iobenguane I 131 injection for intravenous use

- Presented updated biochemical tumor marker data from our pivotal Phase 2 trial at the Endocrine Society's 2021 Annual Meeting, ENDO 2021
- Commenced new marketing initiatives to increase awareness of the diseases and treatment options
- Developed a new Medical Affairs plan to facilitate peer-to-peer education
- Added new centers of excellence to expand treatment options for patients and allow us to supply AZEDRA to new patients located in new geographies

Robust Pipeline with Promising Value Drivers



(1) Using Lantheus microbubble.

PyL: Best-in-Class PSMA Imaging Agent for Prostate Cancer

PyL NDA Accepted by FDA and Granted Priority Review with PDUFA Action Date of May 28, 2021



Anterior whole-body-^{18}F-DCFPyL (PyL) –MIP image from CONDOR trial

PyL (18F-DCFPyL) is a prostate specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent for prostate cancer

- Enables visualization of localized prostate cancer, as well as bone and soft tissue metastases
- PSMA is highly specific to prostate cancer cells, not confounded by degenerative or inflammatory conditions
- 110-minute half-life enables broad distribution to PET imaging centers or hospitals

PyL: Strong Diagnostic Performance Across Prostate Cancer Disease Continuum

CONDOR Study

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study



OSPREY Study

A Phase 2/3 Prospective Multicenter Study of Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)

PyL Pivotal Studies

CONDOR

OSPREY

~600 subjects

Establish the safety and diagnostic performance of PyL imaging across the prostate cancer disease continuum

PyL NDA

Two pivotal trials support the filing of the NDA which was granted Priority Review

PyL Commercial Preparedness Activities

Added significant talent throughout the organization including **Commercial, Medical, Supply Chain, Quality and Technical** departments



Working with PMF channel to ensure nationwide product **availability by year end**

Building **PSMA PET imaging awareness with**:

- PET Imaging Centers
- Urologists
- Medical Oncologists
- Radiation Oncologists
- Patient Advocacy Groups

1095 Phase 2 Trial Progressing

PSMA-targeted small molecule therapeutic for metastatic castration-resistant prostate cancer (mCRPC)

PSMA-targeted iodine-131 labeled small molecule that is designed to deliver beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues

ARROW
Phase 2 Study

24 clinical sites in the U.S. and Canada support enrollment for our multicenter, randomized, controlled study



Study paused in April 2020 to minimize risk to subjects and healthcare providers during the pandemic; new enrollment restarted in October 2020

Recent Developments Across Our Pharma Services & Digital Solutions Portfolio

STRATEGIC PARTNERSHIPS & OTHER

Noria Therapeutics	Acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent which targets fibroblast activation protein (FAP)
Allegheny Health Network (AHN)	Strategic collaboration for use of microbubbles in combination with AHN's ultrasound-assisted non-viral gene transfer (UAGT) technology for the development of a proposed treatment for xerostomia
aPROMISE	EXINI Diagnostics AB, a Lantheus company, received CE Mark clearance for aPROMISE in Europe

- Q1 2021 Highlights & Business Update
- **Q1 2021 Financial Update**
- Closing Remarks
- Q&A

Diversified Portfolio Positions the Company for Sustained and Diversified Revenue Growth

THREE PORTFOLIO CATEGORIES

1 PRECISION DIAGNOSTICS

- DEFINITY® (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION
- DEFINITY RT (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION
- TechneLite® Technetium Tc 99m Generator
- Xenon Xe 133 Gas
- NEUROLITE® Kit for the Preparation of Technetium Tc 99m Bicisate for Injection
- Cardiolite® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection
- Thallium — Thallous Chloride Tl 201 Injection
- Gallium — Gallium Citrate Ga 67 Injection

2 RADIOPHARMACEUTICAL ONCOLOGY

- AZEDRA® iobenguane I 131 injection for intravenous use
- QUADRAMET® (SAMARIUM SM 153 LEXIDRONAM INJECTION)
- FDG*
- PyL™**
- 1095**
- LMI 1195**

3 STRATEGIC PARTNERSHIPS & OTHER

Pharma Services - Microbubble

- CARTHERA Advanced Brain Therapy Through Innovation
- CEREVAST™
- INSIGHTEC®
- AHN

Pharma Services - Biomarkers

- NTI-1309** NORIA
- NM-01** NANOMAB
- BAYER ***
- POINT BIOPHARMA ***
- REGENERON ***

- aBSI AUTOMATED BONE SCAN INDEX
- aPROMISE
- RELISTOR® methylnaltrexone bromide — BAUSCH Health
- PyL™** — CURIUM™ EU ONLY
- Flurpiridaz** — GE Healthcare
- 1404** — ROTOP

*FDG sales are 2020 through January 2021 due to divestiture of Puerto Rico operations; **product candidates; ***Revenue will be reported under the Radiopharmaceutical Oncology category.

Q1 2021 Financial Highlights[1]

Unrestricted Cash and Cash Equivalents at 3/31/2021: $68.9M

USD in millions, except EPS

Q1 2020 | Q1 2021

Revenues



Net Income/(Loss)



GAAP EPS



Free Cash Flow



Adjusted Net Income[2]



Adjusted EPS[2]



(1) See supplemental information at www.lantheus.com. (2) See slide 33 for a reconciliation of GAAP to non-GAAP financials.

Q1 2021 Revenue Highlights

Reported: WW $92.5M, 2.0% growth YoY

USD in millions, YoY Quarterly Growth



KEY DRIVERS

DEFINITY	• Sequentially higher volumes with regional differences
TechneLite	• Volume returning to pre-COVID-19 levels
Other Precision Diagnostics	• Continued COVID-19 impact on Xenon • Sale of Puerto Rico operations in January 2021 (SPECT)
Radiopharmaceutical Oncology	• Sale of Puerto Rico operations in January 2021 (FDG)
Strategic Partnerships & Other	• Growth driven by newly acquired assets

Q1 2021 Operating Expense Highlights

Reported: $40.7M, +31.7% YoY
Adjusted: $37.5M, +51.0% YoY

USD in millions, YoY Quarterly Growth



KEY DRIVERS

Sales & Marketing

- PyL launch preparation
- Hiring activities underway

General & Administrative

- Realization of targeted synergies
- Larger consolidated operating base

Research & Development

- Investments in newly acquired pipeline assets including PyL and 1095
- Larger consolidated operating base

Presentation format GAAP dollars and percent YoY change listed first, the equivalent adjusted results below

Strong Balance Sheet and Financial Flexibility Sets Foundation for Growth

Decline in Debt



Strong Balance Sheet
(Q1 2021)

2.5x

NET LEVERAGE*

	Three Months Ending March 31,	
$M	2021[1]	2020[1]
Cash From Operations	$9.8	$9.4
Cash From or Used in Investing[2]	$13.3	($2.7)
Cash Used In Financing[3]	($34.8)	($3.7)

[1]Free Cash Flow was $7.3 and $6.7 for the three months ended March 31, 2021 and 2020, respectively.

[2]In Q1 2021, we completed the sale of the Puerto Rico radiopharmacy, which provided cash proceeds of $15.8M.

[3]In Q1 2021, we voluntarily repaid in full the entire outstanding principal on the RELISTOR Royalty-Backed Loan.

Resources
(Q1 2021)

Cash on hand[1] **$69M**

Available revolving credit **$200M**

[1]Cash, cash equivalents and restricted cash at the end of the period was $71.0M.

*The net leverage ratio presented relates directly to the Company's June 2019 Credit Facility covenant calculation.

Q2 2021 and Updated FY 2021 Financial Guidance[1]

Guidance Issued May 4, 2021

The Company guidance for the second quarter and updated for the full year 2021 is as follows:

Q2 FY 2021	**Revenue[2]**	$93 million - $97 million
	Adjusted Fully Diluted EPS[2,3]	$0.03 - $0.06
FY 2021	Prior Revenue[2]	$385 million - $400 million
	Current Revenue[2]	**$390 million - $400 million**
	Prior Adjusted Fully Diluted EPS[2,3]	$0.34 - $0.39
	Current Adjusted Fully Diluted EPS[2,3]	**$0.36 - $0.41**

(1) On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company's view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.

(2) Sale of Lantheus' Puerto Rico radiopharmacy and PET manufacturing facility closed on January 29, 2021. During 2020, the Puerto Rico business generated $10.7M of Net Revenue and $1.8M of Adjusted Net Income; FY 2021 guidance excludes contribution from the Puerto Rico, assumption of broad COVID-19 vaccination distribution and approval of PyL on the May 28, 2021 PDUFA date.

(3) FY 2021 guidance assumes fully diluted, weighted avg. shares outstanding of 69M-70M, and depreciation and amortization of ~$15M and ~$25M, respectively.

- Q1 2021 Highlights & Business Update
- Q1 2021 Financial Update
- **Closing Remarks**
- Q&A

Key Takeaways for First Quarter 2021

Significantly invested in our business while overachieving on target run-rate savings

Closed on two key strategic collaborations

Near-term focus on the potential FDA approval and commercial launch of PyL

Further advanced our product pipeline

Strong quarter marked by revenue and earnings driven mainly by DEFINITY volume

Accomplished all while protecting the safety of our employees

- Q1 2021 Highlights & Business Update
- Q1 2021 Financial Update
- Closing Remarks
- **Q&A**

Key Takeaways for First Quarter 2021

Significantly invested in our business while overachieving on target run-rate savings

Closed on two key strategic collaborations

Near-term focus on the potential FDA approval and commercial launch of PyL

Further advanced our product pipeline

Strong quarter marked by revenue and earnings driven mainly by DEFINITY volume

Accomplished all while protecting the safety of our employees

Lantheus Holdings



FIND › FIGHT › FOLLOW™

Appendix

Condensed Consolidated Statement of Operations – Q1 2021

(in thousands, except per share data - unaudited)	Q1 2021 Amount	Q1 2021 % Revenue	Q1 2020 Amount	Q1 2020 % Revenue	% Increase/ (Decrease)
Revenues	$ 92,509	100.0	$ 90,704	100.0	2.0
Cost of goods sold	51,479	55.6	52,702	58.1	(2.3)
Gross profit	41,030	44.4	38,002	41.9	8.0
Operating expenses					
Sales and marketing	14,173	15.3	10,130	11.2	39.9
General and administrative	16,138	17.4	16,699	18.4	(3.4)
Research and development	10,360	11.2	4,048	4.5	155.9
Total operating expenses	40,671	44.0	30,877	34.0	31.7
Gain on sale of assets	15,263	16.5	-	-	N/A
Operating income	15,622	16.9	7,125	7.9	119.3
Interest expense	2,718	2.9	1,946	2.1	39.7
Gain on extinguishment of debt	(889)	(1.0)	-	-	N/A
Other income	(549)	(0.6)	(350)	(0.4)	56.9
Income before income taxes	14,342	15.5	5,529	6.1	159.4
Income tax expense	5,334	5.8	2,192	2.4	143.3
Net income	$ 9,008	9.7	$ 3,337	3.7	169.9
Net income per common share - diluted	$ 0.13		$ 0.08		
Weighted-average common shares outstanding - diluted	67,714		40,102		

As Adjusted Condensed Consolidated Statement of Operations – Q1 2021

(in thousands, except per share data - unaudited)	Q1 2021 Amount	Q1 2021 % Revenue	Q1 2020 Amount	Q1 2020 % Revenue	% Increase/ (Decrease)
Revenues	$ 92,509	100.0	$ 90,704	100.0	2.0
Cost of goods sold	46,017	49.7	44,312	48.9	3.8
Gross profit	46,492	50.3	46,392	51.1	0.2
Operating expenses					
Sales and marketing	13,531	14.6	9,877	10.9	37.0
General and administrative	14,003	15.1	11,280	12.4	24.1
Research and development	9,935	10.7	3,659	4.0	171.5
Total operating expenses	37,469	40.5	24,816	27.4	51.0
Operating income	9,023	9.8	21,576	23.8	(58.2)
Interest expense	2,718	2.9	1,946	2.1	39.7
Other income	(242)	(0.3)	(350)	(0.4)	(30.9)
Income before income taxes	6,547	7.1	19,980	22.0	(67.2)
Income tax expense	3,251	3.5	5,698	6.3	(42.9)
Net income	$ 3,296	3.6	$ 14,282	15.7	(76.9)
Net income per common share - diluted	$ 0.05		$ 0.36		
Weighted-average common shares outstanding - diluted	67,714		40,102		

(1) See supplemental information at www.lantheus.com. (2) See slide 30 for a reconciliation of GAAP to non-GAAP financials.

Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share data – unaudited)

	Three Months Ended March 31,	
	2021	2020
Net income	$ 9,008	$ 3,337
Stock and incentive plan compensation	3,317	3,075
Amortization of acquired intangible assets	4,685	392
Acquired debt fair value adjustment	(307)	—
Contingent consideration fair value adjustments	300	—
Non-recurring severance related fees	436	—
Extinguishment of debt	(889)	—
Gain on sale of assets	(15,263)	—
Integration costs	19	2,372
Acquisition-related costs	(103)	1,412
Impairment of long-lived assets	—	7,275
Other	10	(75)
Income tax effect of non-GAAP adjustments[(a)]	2,083	(3,506)
Adjusted net income	$ 3,296	$ 14,282
Adjusted net income, as a percentage of revenues	3.6 %	15.7 %

	Three Months Ended March 31,	
	2021	2020
Net income per share - diluted	$ 0.13	$ 0.08
Stock and incentive plan compensation	0.05	0.08
Amortization of acquired intangible assets	0.08	0.01
Acquired debt fair value adjustment	(0.01)	—
Contingent consideration fair value adjustments	0.01	—
Non-recurring severance related fees	0.01	—
Extinguishment of debt	(0.01)	—
Gain on sale of assets	(0.23)	—
Integration costs	—	0.06
Acquisition-related costs	(0.01)	0.04
Impairment of long-lived assets	—	0.18
Other	—	—
Income tax effect of non-GAAP adjustments[(a)]	0.03	(0.09)
Adjusted net income per share - diluted	$ 0.05	$ 0.36
Weighted-average common shares outstanding - diluted	67,714	40,102

(a) The income tax effect of the adjustments between GAAP net income and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

Consolidated Statement of Operations
(in thousands, except per share data – unaudited)

	Three Months Ended March 31,	
	2021	2020
Revenues	$ 92,509	$ 90,704
Cost of goods sold	51,479	52,702
Gross profit	41,030	38,002
Operating expenses		
Sales and marketing	14,173	10,130
General and administrative	16,138	16,699
Research and development	10,360	4,048
Total operating expenses	40,671	30,877
Gain on sale of assets	15,263	—
Operating income	15,622	7,125
Interest expense	2,718	1,946
Gain on extinguishment of debt	(889)	—
Other income	(549)	(350)
Income before income taxes	$ 14,342	$ 5,529
Income tax expense	5,334	2,192
Net income	$ 9,008	$ 3,337
Net income per common share:		
Basic	$ 0.13	$ 0.08
Diluted	$ 0.13	$ 0.08
Weighted-average common shares outstanding:		
Basic	67,094	39,433
Diluted	67,714	40,102

Consolidated Revenues Analysis
(in thousands – unaudited)

	Three Months Ended March 31,		
	2021	2020 [1]	% Change
DEFINITY	$ 55,971	$ 52,505	6.6 %
TechneLite	22,800	22,779	0.1 %
Other precision diagnostics	6,984	13,057	(46.5)%
Total precision diagnostics	85,755	88,341	(2.9)%
Radiopharmaceutical oncology	1,500	1,968	(23.8)%
Strategic partnerships and other	5,254	395	1,230.1 %
Total net revenues	$ 92,509	$ 90,704	2.0 %

1. The Company reclassified rebates and allowances of $4.7 million for the three months ended March 31, 2020 within each product category, which included $4.3 million for DEFINITY, $0.3 million for TechneLite and $0.1 million for other precision diagnostics.

Reconciliation of Free Cash Flow
(in thousands – unaudited)

	Three Months Ended March 31,	
	2021	2020
Net cash provided by operating activities	$ 9,818	$ 9,408
Capital expenditures	(2,520)	(2,698)
Free cash flow	$ 7,298	$ 6,710

Condensed Consolidated Balance Sheet
(in thousands – unaudited)

	March 31, 2021	December 31, 2020
Assets		
Current assets		
Cash and cash equivalents	$ 68,861	$ 79,612
Accounts receivable, net	58,991	54,002
Inventory	30,357	35,744
Other current assets	10,145	9,625
Assets held for sale	—	5,242
Total current assets	168,354	184,225
Property, plant and equipment, net	118,381	120,171
Intangibles, net	371,331	376,012
Goodwill	61,189	58,632
Deferred tax assets, net	62,832	70,147
Other long-term assets	61,361	60,634
Total assets	$ 843,448	$ 869,821
Liabilities and stockholders' equity		
Current liabilities		
Current portion of long-term debt and other borrowings	$ 10,251	$ 20,701
Accounts payable	19,099	16,284
Accrued expenses and other liabilities	35,240	41,726
Liabilities held for sale	—	1,793
Total current liabilities	64,590	80,504
Asset retirement obligations	14,408	14,020
Long-term debt, net and other borrowings	171,474	197,699
Other long-term liabilities	64,857	63,393
Total liabilities	315,329	355,616
Total stockholders' equity	528,119	514,205
Total liabilities and stockholders' equity	$ 843,448	$ 869,821

Supplemental Revenue Information
(unaudited)

Gross Revenue - Excluding Rebates and Allowances

	2019					2020				
(in millions)	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Q4	Total
DEFINITY	$ 51.1	$ 54.6	$ 52.4	$ 59.4	$ 217.5	$ 56.8	$ 40.4	$ 55.4	$ 60.7	$ 213.3
TechneLite	24.1	20.1	21.7	20.6	86.5	23.1	18.9	21.5	22.7	86.2

Net Revenue - Including Rebates and Allowances

	2019					2020				
(in millions)	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Q4	Total
DEFINITY	$ 47.6	$ 50.7	$ 48.8	$ 55.3	$ 202.4	$ 52.5	$ 37.1	$ 50.4	$ 55.9	$ 195.9
TechneLite	23.9	19.8	21.5	20.3	85.5	22.8	18.7	21.1	22.4	85.0

OSPREY and CONDOR: Safety of 18F-DCFPyL in All Subjects

Preferred Term	All Subjects N=593 n (%)
Any treatment-emergent Adverse Event	30 (5.1)
Headache	9 (1.5)
Dysgeusia	9 (1.3)
Fatigue	4 (0.7)
Dizziness	1 (0.2)
Hyperaesthesia	1 (0.2)
Migraine	1 (0.2)
Visual field defect	1 (0.2)
Application site rash	1 (0.2)
Chest discomfort	1 (0.2)
Feeling abnormal	1 (0.2)
Injection site pain	1 (0.2)
Arthralgia	1 (0.2)
Muscular weakness	1 (0.2)
Pain in extremity	1 (0.2)
Rash	1 (0.2)
Dry skin	1 (0.2)
Rash generalized	1 (0.2)
Dehydration	1 (0.2)
Dysuria	1 (0.2)
Vertigo	1 (0.2)
Hypersensitivity	1 (0.2)
Disorientation	1 (0.2)

- 30 (5.1%) patients experienced at least one treatment-emergent adverse event
- The most frequently reported adverse events (>0.5%) were headache, dysgeusia, and fatigue
- Hypersensitivity reaction was the single drug related Grade 3 adverse events reported in one patient with significant history of allergic reactions

Approved Products

AZEDRA® iobenguane I 131 injection for intravenous use

aBSI AUTOMATED BONE SCAN INDEX

Cardiolite® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection

DEFINITY® VIAL FOR (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION

DEFINITY RT (Perflutren Lipid Microsphere) INJECTABLE SUSPENSION

Gallium Gallium Citrate Ga 67 Injection

NEUROLITE® Kit for the Preparation of Technetium Tc 99m Bicisate for Injection

QUADRAMET® (SAMARIUM SM 153 LEXIDRONAM INJECTION)

RELISTOR® methylnaltrexone bromide

TechneLite® Technetium Tc 99m Generator

Thallium Thallous Chloride Tl 201 Injection

Xenon Xe 133 Gas

Strategic Partnerships Across Our Portfolio

Oncology

PyL

REGENERON

BAYER

POINT BIOPHARMA

CURIUM™

1404

ROTOP

PSMA TTC

BAYER

aBSI

GE Healthcare

Biomarker

NORIA THERAPEUTICS, INC.

NANOMAB

Microbubble

CEREVAST™

INSIGHTEC®

CARTHERA
Advanced Brain Therapy Through Innovation

AHN

RELISTOR

BAUSCH+ Health

Flurpiridaz F18

GE Healthcare

Lantheus Holdings



FIND > FIGHT > FOLLOW™

Q1 2021 Financial Results

May 4, 2021